

# Tolvaptan

**Catalog No: tcsc0572**



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

150683-30-0

**Formula:**

$C_{26}H_{25}ClN_2O_3$

**Pathway:**

GPCR/G Protein;Autophagy

**Target:**

Vasopressin Receptor;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (222.75 mM)

**Alternative Names:**

OPC-41061

**Observed Molecular Weight:**

448.94


## Product Description

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28 $\mu$ M for the inhibition of AVP-induced platelet aggregation.

IC50 value: 1.28  $\mu$ M (inhibition of AVP-induced platelet aggregation)

Target: vasopressin receptor 2

Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28 $\mu$ M for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan (OPC-41061) is also in fast-track clinical trials for polycystic kidney disease. Treatment with t tolvaptan (OPC-41061) causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst. However, tolvaptan (OPC-41061) has not been shown to decrease heart failure re-hospitalization or mortality. As an adjunct to standard therapy, tolvaptan (OPC-41061) is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!